Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Trump signs a law returning whole milk to school lunches - 2NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- 3Bayer reports positive results for blood thinner after 2023 setback
- 4Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 5vote in favor of Your #1 kind of climate
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- Central African Republic's president sworn in for a third term after disputed election
- The 15 Best Business visionaries Under 40
- Avoid Slam: Exploring the Pickup Truck Transformation
- 8 Espresso Bean Starting points All over the Planet
- Top 10 Moving Style Architects of the Year
- German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030
- Watch comet C/2026 A1 plunge toward the sun online this week
